Clinical Considerations in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Course

CME : 0.25
Start Date :  Jun 30, 2020End Date :  Jun 30, 2021

Duration :  15 Minutes

Organized by :   ReachMD

Specialties :   Oncology, Head and Neck Pathology

Fees Fee :   Fee Details Not Available

Conference Summary

Clinical Considerations in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Course is organized by ReachMD.

Release Date: 06/30/2020
Expiration Date: 06/30/2021

Target Audience:
This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and healthcare professionals treating patients with head and neck cancer around the world, with a specific focus on Europe and China/Asia Pacific.

Accreditation and Credit Designation Statements:
• Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
• Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
Squamous cell carcinoma of the head and neck is one of the most common cancers worldwide, with over 500,000 new cases and 380,000 deaths annually. In this regard, the poor outcomes associated with recurrent/metastatic squamous cell carcinoma of the head and neck represent a significant unmet medical need. For these patients, first-line pharmacologic therapy includes chemotherapy, targeted therapies, and immunotherapy, often in combination. Nonetheless, treatment selection is widely recognized as difficult due to complex patient and disease factors.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Describe barriers to achieving the optimal management of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).
• Assess and differentiate first-line treatment options for recurrent/metastatic SCCHN, including patient selection and associated adverse events.

Credit Info

  • CME : 0.25
Contact Us

Toll free Number

1(800) 826-2059

Email

support@eMedEvents.com

Chat Assistant

Live Chat
Recommended